Julie McHugh

CIK 1487179 · Chief Operating Officer · last filed 2026-06-17

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$3.89M

Companies

Total Filings

Lifetime Open-Market Net

-$2.17M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

LNTH price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON, MA 02110

Related Filers

IRONWOOD PHARMACEUTICALS INC — 30 joint filings, latest 2026-06-17

Lantheus Holdings, Inc. — 25 joint filings, latest 2026-05-18

ENDO PHARMACEUTICALS HOLDINGS INC — 8 joint filings, latest 2013-03-15

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
IRWD	Director	250,749	$3.50	$877.6K	-$827.2K	26	2026-06-17
LNTH	Director	30,099	$99.92	$3.01M	-$1.34M	22	2026-05-18
Evelo Biosciences, Inc. (EVLO) Delisted	Director	—	$0.00	—	$0	3	2023-06-12
AERIE PHARMACEUTICALS INC (AERI) Delisted	Director	0	$15.25	$0	$0	9	2022-11-21
TREVENA INC (TRVN) Delisted	Director	—	$0.01	—	$0	7	2020-05-15
EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted	Director	—	—	—	$0	2	2015-06-08
VIROPHARMA INC (VPHM) Delisted	Director	8,666	—	—	$0	5	2014-01-03
ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted	Chief Operating Officer	48,046	$0.29	$14.1K	$0	7	2013-03-15

Recent Filings · Page 4 of 9

86 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2021-04-13	Evelo Biosciences, Inc. (EVLO) Delisted	Grant (A)	—	$0	EDGAR
2021-04-13	LNTH	Sell (S)	−2,800	-$59.4K	EDGAR
2020-10-05	LNTH	Grant (A)	+1,259	$0	EDGAR
2020-09-09	IRWD	Sell (S)	−7,950	-$77.7K	EDGAR
2020-08-12	LNTH	Grant (A)	+749	$0	EDGAR
2020-06-29	AERIE PHARMACEUTICALS INC (AERI) Delisted	Grant (A)	+1,750	$0	EDGAR
2020-06-05	IRWD	Grant (A)	+21,720	$0	EDGAR
2020-05-15	TREVENA INC (TRVN) Delisted	Grant (A)	—	$0	EDGAR
2020-03-05	LNTH	Grant (A)	+8,095	$0	EDGAR
2020-03-02	LNTH	Sell (S)	−1,756	-$27.8K	EDGAR

Showing 31–40 of 86

Prev Page 4 of 9 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.